Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex etiology. 1 FVC and subjective symptom assessments such as dyspnea scores are commonly used to characterize disease severity or progression in patients with IPF. Although these outcomes are typically measured intermittently at intervals of 3 to 6 months, recent data suggest that more frequent longitudinal assessments may improve the precision of change estimates over time. 2 Repeated monitoring is feasible and informative in patients with IPF, using hand-held spirometers to measure FVC and self-administered questionnaires to measure dyspnea.
2,3
Short-term changes in symptoms do not seem to be associated with short-term changes in lung function, and it is unknown what factors affect the short-term variability of FVC in these patients.
Air pollution is a ubiquitous exposure and a wellestablished risk factor for adverse health outcomes, including all-cause and respiratory mortality. [4] [5] [6] [7] [8] Shortterm increases in air pollution exposures are associated with subsequent increases in exacerbations and hospitalizations in patients with asthma or COPD, [9] [10] [11] [12] as well as an increased risk of bronchiolitis obliterans in patients following a lung transplant. 13 Air pollution exposure has been proposed as a risk factor for the development of interstitial lung disease, with plausible biologic mechanisms. 14 Ozone (O 3 ) and nitrogen dioxide (NO 2 ) are associated with an increased risk of acute exacerbation of IPF, whereas mortality risk increases with greater exposures to particulate matter < 2.5 or 10 mm in aerodynamic diameter (PM 2.5 and PM 10 , respectively). 15, 16 Recent data further suggest that higher exposures to PM 10 are associated with more rapid decline in lung function in patients with IPF. 17 The effect of air pollution exposures on disease severity and on short-term changes in lung function and dyspnea in patients with IPF is unknown.
The objective of the present study was to define the relationship between air pollution exposure, lung function, and dyspnea in patients with IPF by using weekly home spirometry and self-administered questionnaires. We further examined the relationship between air pollution exposure and changes in lung function and dyspnea over time. Some of these results have previously been presented in abstract form. 18 
Patients and Methods

Study Population
Patients were prospectively recruited from the longitudinal interstitial lung disease program at the University of California San Francisco between January and September 2014. Eligibility criteria included a diagnosis of IPF (according to current consensus guidelines), 1 residence in the state of California, and no concomitant participation in a blinded drug treatment trial of IPF therapy. Each patient's most recent high-resolution CT scan of the chest was reviewed by an investigator (K. A. J.) to ensure that the extent of emphysema was < 10%, although the scans were not formally scored by a chest radiologist. The local institutional review board approved this study, and all patients provided written informed consent (University of California San Francisco Human Research Protection Program Committee on Human Research; institutional review board no. 13-11433).
Measurements
Patients were enrolled in a longitudinal prospective cohort for up to 40 weeks. At the baseline visit, each patient's age, sex, smoking history, and complete residential address were recorded. An officebased spirometry meeting American Thoracic Society/European Respiratory Society standards 19 was performed at baseline, measuring absolute values and the percent predicted of FVC.
Home Monitoring
Each patient was provided a personalized hand-held spirometer that met American Thoracic Society/European Respiratory Society performance standards (Spiro PD version 1.0; PMD Healthcare) and received one-on-one instruction in its use. Hand-held spirometry was performed weekly for up to 40 weeks. The spirometer provided real-time feedback to the patient to support proper spirometric technique and to optimize compliance. Three maneuvers were performed at each weekly assessment, with the highest values recorded for FEV 1 and FVC. The device was not blinded, and patients were able to see their recorded values.
Prior to spirometry, patients also completed two weekly questionnaires to measure dyspnea severity, for up to 40 weeks: the University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) 20 and a 10-point visual analog scale (VAS) (e- Fig 1) . Permission was obtained for use of the UCSD-SOBQ in this study. Patients recorded a weekly diary documenting the estimated duration of time spent away from home over the previous week. Weekly measurements were omitted if the patient indicated that he or she was away from home for > 72 h that week. Upon study completion, patients returned their diaries and symptom scores and had their home spirometry data uploaded from the device.
Air Pollution Exposures
Air quality data were obtained from the California Air Resources Board for individual patients based on their geocoded residential address. The Air Resources Board is a branch of the California Environmental Protection Agency, providing quality-controlled air quality data from across the state. Data were collected for O 3 , NO 2 , PM 2.5 , and PM 10 . Pollutant concentrations were calculated at the following levels, in order of decreasing preference: A ¼ from nearest air monitoring site; B ¼ from the county average; C ¼ from the air basin average; or D ¼ no near site, county, or air basin average, depending on data availability. Mean levels of each pollutant were determined for the week prior to any recorded lung function or dyspnea measure. All exposure levels were adjusted for temperature and humidity. Weekly levels for each pollutant were compared vs the US Environmental Protection Agency's national ambient air quality standards. 21 
Statistical Analysis
Means, proportions, and SDs were used where appropriate to describe the study population. Mean week-to-week changes in FVC, FEV 1 , UCSD-SOBQ, and VAS were calculated for the cohort across the study period. In addition, changes in FVC, FEV 1 , UCSD-SOBQ, and VAS scores were calculated from the beginning to the end of the study for each participant in the cohort.
Cumulative mean exposure levels for each patient were calculated based on the weekly measures for each pollutant over the study period. In addition, mean week-to-week change in each pollutant was calculated for the cohort over the study period. The dependence of weekly measurements of FVC, FEV 1 , UCSD-SOBQ, and VAS on preceding levels of each pollutant was assessed by using linear mixed models. Mean pollutant exposures and outcome measures were assessed over periods of 2 to 5 weeks' duration, separated by intervals of 0, 3, and 6 weeks. These assessment periods and lag times were selected for consistency with previous studies on acute exacerbation and to reduce the measurement variability from a single cross-sectional measure of outcome. The association of mean exposure levels with mean lung function and dyspnea over 3 and 40 weeks was similarly examined by using linear regression to represent short-term and longer term associations, respectively. Similarly, the association between each pollutant's maximum level and average lung function, and changes in lung function, over the study period was assessed. Sensitivity analyses were conducted censoring patients at the time of first selfreported respiratory deterioration/acute exacerbation of IPF and at the time of pirfenidone initiation if the drug was started postenrollment.
Results
Study Population
Baseline characteristics of the cohort are presented in Table 1 . Thirty patients were screened, and 25 were enrolled in the study. The mean AE SD age was 73.6 AE 7.5 years, 84% were male, and 8 of 25 (32%) were never smokers. Mean duration of follow-up was 33 AE 9 weeks, and 899 weeks of data were included in the analyses. Baseline office-based and hand-held FVC were highly correlated (r ¼ 0.91). The mean baseline values for FVC, UCSD-SOBQ, and VAS were 2.73 AE 0.7 L (68.2 AE 15.2% predicted), 36.3 AE 29.5, and 2.8 AE 2.2, respectively.
The average changes in FVC, UCSD-SOBQ, and VAS over the study period were -0.41 AE 0.31 L, 12.9 AE 31.5, and 0.47 AE 2.4, respectively. The median number of weeks a patient spent > 72 h away from home (and thus those measures were omitted) was 2.3 (range: 0-12 weeks).
Air Pollution Exposure Levels
Given the rolling enrollment, 899 weeks of air pollution measures were obtained for each pollutant. The majority of measures were obtained from the nearest monitoring site ranging from 60% for PM 10 to 90% for PM 2.5 (e- Table 1 ). Mean exposure and weekly changes in pollutant levels throughout the study period are presented in Table 2 . No measures of NO 2 , O 3 , or PM 10 exceeded current standards of the US Environmental Protection Agency, although 175 measures of PM 2.5 exceeded currently recommended air quality standards.
Air Pollution and Lung Function Levels
Increased mean exposures to PM 10 were consistently associated with lower FVC and FEV 1 % predicted, with both assessed over 2 to 5 weeks, and the exposure and outcome assessment periods separated by intervals of 0, 3, and 6 weeks (Tables 3, 4 Table 2 ).
Air Pollution and Changes in Lung Function
There were no significant relationships between mean week-to-week change in air pollutant levels and concurrent weekly changes in FVC, FEV 1 , UCSD-SOBQ, or VAS (e- Table 3 ). We also found no statistically significant associations between mean air pollutant levels and subsequent changes in lung function, regardless of the duration of the assessment periods or the interval between them. Neither higher cumulative mean exposures nor maximal exposures to air pollution were associated with more rapid decline in FVC or FEV 1 over the study period. Similarly, there were no significant relationships between cumulative mean exposures and changes in measures of dyspnea over the study period.
In sensitivity analyses, censoring patients at the time of pirfenidone initiation or at the time of self-reported acute exacerbation of IPF/respiratory deterioration did not significantly affect the study results.
Discussion
Higher average exposures to NO 2 , PM 2.5 , and PM 10 were associated with lower FVC in these study patients with IPF, suggesting that air pollution may affect disease severity in some individuals. In contrast, changes in dyspnea and dyspnea severity were independent of air pollution exposures, in both the short-term and longer term. We did not find that higher pollution exposures were associated with more rapid lung function decline or that short-term increases in exposure resulted in shortterm worsening of lung function or dyspnea in this cohort studied for up to 40 weeks. These data are unique in that we were able to closely monitor the lung function and symptoms of patients with IPF, with frequent repeated measures taken over time. These results are reassuring that the air pollution exposure levels in the study did not significantly affect dyspnea over a relatively short period of time.
To our knowledge, this study is the first prospective trial to apply mobile technology for contemporaneous assessment of lung function and dyspnea in relation to environmental exposures in patients with IPF. There is a growing body of literature supporting the use of mobile technology and patient-collected data for both clinical and research purposes. Our data affirm the feasibility of home monitoring and illustrate its potential for novel applications, such as symptom assessment and linking with other data sources. Data linkage between mobile technologies and administrative databases could establish novel frameworks within which to conduct research in the field of IPF.
The cross-sectional relationship of lower FVC with higher average NO 2 , PM 2.5 , and PM 10 exposures is a novel finding. Long-term inhalational injury may contribute to the risk of developing IPF in certain susceptible individuals. This suggests that at any point in the disease process, an individual's disease may be more severe due to environmental influences. Our findings do b ¼ difference in FVC % predicted per unit increase in PM 10 levels. See Table 2 legend for expansion of other abbreviation.
not conclusively address this question, as the cohort comprised prevalent, not incident, cases of IPF, and we could not account for time since diagnosis. It is unknown what variables may influence FVC % predicted at any given cross-sectional assessment; however, environmental exposures such as air pollution warrant reasonable consideration. Air pollution exposures may also be a surrogate for other impactful variables, such as access to health care or socioeconomic status, both well-established predictors of poor health outcomes. [22] [23] [24] Longer term studies of larger cohorts will be needed to comprehensively address these questions.
Recent data suggest that increased PM 2.5 and PM 10 exposures are risk factors for mortality in patients with IPF 16 and that higher PM 10 exposure is associated with accelerated lung function decline in patients with IPF.
17
Our study was underpowered to assess mortality. We did not find that air pollution levels were associated with rate of loss of FVC over 40 weeks, which is likely due to the short duration and small sample size of our study compared with a previous study. 17 Also, five patients were taking pirfenidone at baseline enrollment, with another nine starting the drug during the study period, which may have reduced our ability to detect the impact of air pollution on lung function decline. 25 However, our finding that disease severity, defined by using FVC % predicted, is associated with higher PM 10 exposures is consistent with the findings of Winterbottom et al, 17 and this adds to the body of literature supporting a potential pathogenic role in fibrotic interstitial lung disease.
Week-to-week changes in FVC were independent of air pollution exposure in the study cohort. This outcome has a number of possible explanations. The trial may have been underpowered to detect a relationship between exposure and outcome in this relatively small study; however, we think this possibility is unlikely given the amount of repeated measures data collected over the study period using home monitoring. It is more likely that FVC may be too coarse of a measure to detect the subtle cellular effects of air pollution exposure, and alternate measures such as BAL fluid analysis or serum biomarker assessment may have provided more granular data, although they were not part of the study protocol. Although there was spatial chestjournal.org variability in this cohort, the diversity in the air pollution exposure levels may have been inadequate to detect small effects, particular when examining changes from 1 week to the next. California has relatively good air quality, and stronger effects may have been seen with higher pollution exposures, as exist in other regions. Short-term variability in FVC may simply be influenced by other unmeasured factors such as fluctuating comorbid conditions (eg, gastroesophageal reflux, cardiac disease, infection), fatigue, or patient effort, which would limit our ability to detect a change due to pollution over a short time. Finally, it may require > 40 weeks of follow-up to show the impact of air pollution exposure on FVC.
Our study has a number of important limitations, namely the small sample size and relatively short duration of follow-up. The study was not designed to assess the impact of air pollution on acute exacerbation or mortality in patients with IPF. Lastly, we cannot exclude misclassification bias with respect to air pollution estimates, given that we did not record patientlevel time-activity data. Future studies using personalized exposure monitors or, better yet, validated biomarkers of exposure will be required to overcome this potential bias.
Conclusions
Increased exposures to PM 10 , PM 2.5 , and NO 2 were associated with lower lung function in this cohort of patients with IPF followed up prospectively for up to 40 weeks. However, changes in lung function from 1 week to the next, as well as over 40 weeks of follow-up, were independent of air pollution exposures, suggesting that lung function variability may be driven by other factors. Patient-reported dyspnea scores were also independent of air pollution exposures over the short term and longer term. Future studies in this area should consider combining mobile health technologies with individualized exposure assessment tools to best address these questions.
